Equities analysts forecast that Adamis Pharmaceuticals Corp (NASDAQ:ADMP) will report sales of $4.14 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Adamis Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.75 million and the highest estimate coming in at $4.60 million. Adamis Pharmaceuticals posted sales of $3.81 million in the same quarter last year, which suggests a positive year-over-year growth rate of 8.7%. The firm is expected to issue its next earnings results on Monday, August 13th.
On average, analysts expect that Adamis Pharmaceuticals will report full year sales of $18.48 million for the current year, with estimates ranging from $15.85 million to $21.90 million. For the next fiscal year, analysts anticipate that the business will report sales of $32.28 million per share, with estimates ranging from $22.32 million to $47.60 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Adamis Pharmaceuticals.
Adamis Pharmaceuticals (NASDAQ:ADMP) last released its quarterly earnings data on Thursday, May 10th. The specialty pharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.06). Adamis Pharmaceuticals had a negative net margin of 207.24% and a negative return on equity of 71.68%. The business had revenue of $3.18 million for the quarter, compared to the consensus estimate of $3.34 million.
A number of research firms have recently issued reports on ADMP. Zacks Investment Research upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday. B. Riley increased their price objective on shares of Adamis Pharmaceuticals to $7.50 and gave the company a “buy” rating in a research note on Tuesday. Maxim Group increased their price objective on shares of Adamis Pharmaceuticals to $13.00 and gave the company a “buy” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Adamis Pharmaceuticals in a research note on Monday. Finally, ValuEngine upgraded shares of Adamis Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Two analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Adamis Pharmaceuticals presently has an average rating of “Buy” and an average price target of $9.38.
A number of institutional investors and hedge funds have recently made changes to their positions in ADMP. Virtu Financial LLC acquired a new stake in Adamis Pharmaceuticals in the fourth quarter valued at approximately $442,000. Dimensional Fund Advisors LP acquired a new stake in Adamis Pharmaceuticals in the first quarter valued at approximately $244,000. Northern Trust Corp boosted its stake in Adamis Pharmaceuticals by 50.7% in the first quarter. Northern Trust Corp now owns 139,536 shares of the specialty pharmaceutical company’s stock valued at $489,000 after acquiring an additional 46,924 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in Adamis Pharmaceuticals by 1,050.3% in the fourth quarter. Wells Fargo & Company MN now owns 28,182 shares of the specialty pharmaceutical company’s stock valued at $124,000 after acquiring an additional 25,732 shares in the last quarter. Institutional investors own 10.38% of the company’s stock.
Shares of NASDAQ ADMP traded down $0.15 during midday trading on Tuesday, reaching $4.50. 859,640 shares of the company’s stock traded hands, compared to its average volume of 710,430. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.57 and a current ratio of 1.88. Adamis Pharmaceuticals has a one year low of $2.35 and a one year high of $5.85. The company has a market cap of $150.25 million, a PE ratio of -5.00 and a beta of 0.25.
Adamis Pharmaceuticals Company Profile
Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company's specialty pharmaceutical product candidates comprise Symjepi (epinephrine) Injection pre-filled syringe (PFS) for use in the emergency treatment of acute allergic reactions, including anaphylaxis.
Get a free copy of the Zacks research report on Adamis Pharmaceuticals (ADMP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.